Constellation Pharmaceuticals announced that the Company has dosed the first patient in a Phase 1/2 clinical trial of CPI-0209.CPI-0209 is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target...
Novartis has pulled back the curtain on new Phase 2b data for its IgE/FceR1 pathway-blocking drug ligelizumab, showing that the therapy outperformed Roche’s Xolair in key metrics...
